BLOOD REVIEWS
Scope & Guideline
Empowering research, transforming blood health.
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal covers a wide range of hematological malignancies including leukemia, lymphoma, and myeloma, focusing on their biology, treatment strategies, and patient management. - Coagulation Disorders:
Research on various coagulation disorders, such as hemophilia, thrombocytopenia, and thrombotic conditions, is a key focus, including novel therapeutic approaches and management strategies. - Transfusion Medicine:
Exploration of transfusion practices, adverse reactions, and the evolving landscape of transfusion-related therapies, including the use of blood products and their clinical implications. - Immunotherapy and Targeted Therapies:
Significant emphasis on the development and application of immunotherapies, CAR T-cell therapy, and targeted treatments in hematological disorders, reflecting the shift towards personalized medicine. - Patient-Centered Care:
The journal highlights the importance of quality of life, patient preferences, and shared decision-making in treatment approaches for hematological diseases. - Emerging Technologies:
Coverage of innovative technologies such as artificial intelligence and genomics in the diagnosis and treatment of hematological conditions, aiming to integrate cutting-edge science into clinical practice.
Trending and Emerging
- Gene Therapy and Genetic Modulation:
There is a growing interest in gene therapy as a potential curative approach for various hematological disorders, including sickle cell disease and hemophilia, highlighting advancements in genetic technologies. - Microbiome and Hematology:
Research on the gut microbiome's role in hematological conditions is on the rise, exploring how dysbiosis may impact disease progression and treatment outcomes, indicating a shift towards understanding systemic influences on hematologic health. - Immunotherapy Innovations:
The emergence of novel immunotherapeutic strategies, including bispecific antibodies and checkpoint inhibitors, is a significant trend, reflecting the ongoing transformation in treatment paradigms for hematological malignancies. - Health Equity and Access to Care:
Increasing publications focus on disparities in hematological care, emphasizing the need for equity in access to innovative therapies, particularly among diverse populations. - Patient-Reported Outcomes and Quality of Life:
There is an increasing emphasis on patient-reported outcomes and quality of life measures in research, underscoring the importance of holistic approaches to patient care in hematology. - Artificial Intelligence in Hematology:
The application of artificial intelligence and machine learning in diagnostics, treatment personalization, and monitoring of hematologic diseases is an emerging theme, indicative of the journal's forward-looking approach.
Declining or Waning
- Traditional Chemotherapy Approaches:
With the rise of targeted therapies and immunotherapies, traditional chemotherapy approaches for hematological malignancies are discussed less frequently, as newer treatments gain prominence. - Basic Hematology:
Fundamental topics in hematology that do not directly relate to clinical or translational research are becoming less common, as the journal increasingly favors articles with direct clinical applications or innovative methodologies. - Epidemiological Studies:
While still important, epidemiological studies focusing on rare conditions or those with limited translational impact are less frequently published, as the journal prioritizes studies that offer immediate clinical relevance. - Classic Diagnostic Techniques:
The focus on traditional diagnostic methods is waning in favor of more advanced techniques, such as genomic profiling and machine learning applications in diagnostics. - Older Treatment Modalities:
The exploration of older treatment modalities, particularly those that have been largely replaced by newer therapies, is less common as the field moves toward more effective and innovative treatment options.
Similar Journals
Blood Transfusion
Enhancing Lives Through Blood Transfusion Innovations.Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.
Hematology Transfusion and Cell Therapy
Advancing knowledge in hematology and cell therapy.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
LEUKEMIA & LYMPHOMA
Advancing knowledge in blood cancer research.LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.
Indian Journal of Hematology and Blood Transfusion
Transforming Blood Health: Where Research Meets PracticeIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
BLOOD
Pioneering Research at the Heart of Hematology.BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.
Blood Research
Exploring the Frontiers of Hematology ResearchBlood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.
Blood Cancer Discovery
Exploring Innovations in Oncology and BeyondBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.
Turkish Journal of Hematology
Championing open access to vital hematology knowledge.Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.
Asian Journal of Transfusion Science
Pioneering open-access research in hematology and immunology.Asian Journal of Transfusion Science, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, is a prominent open-access journal dedicated to the interdisciplinary fields of hematology and immunology. With an ISSN of 0973-6247 and E-ISSN 1998-3565, it serves as a crucial platform for researchers, clinicians, and students from around the globe, facilitating the dissemination of high-quality, peer-reviewed research. Established in 2007, the journal has consistently aimed to advance scientific knowledge in transfusion practices, enhancing patient care and safety in transfusion medicine. Despite its recent categorization in the Q4 quartile within both Hematology and Immunology, the journal is making strides toward greater visibility in the academic community, with plans for expanded reach and increased citation impact. With its commitment to open-access publishing, the Asian Journal of Transfusion Science ensures that invaluable research findings are readily accessible to all stakeholders, thereby bolstering collaborative efforts in transfusion science and related disciplines.
Journal of Hematology
Empowering Research, Transforming LivesThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.